HONG KONG | April 10, 2026
Insilico Medicine has announced the nomination of ISM6200, a potential best-in-class selective NR3C1 inhibitor, as a preclinical candidate targeting ovarian cancer, Cushing’s syndrome, hypercortisolism-associated obesity, and glaucoma. Developed using the company’s Pharma.AI platform and Chemistry42 generative engine, ISM6200 represents a significant advancement in AI-driven drug discovery, demonstrating strong efficacy across multiple preclinical models, favorable pharmacokinetics, and low drug–drug interaction (DDI) risk. This milestone highlights the growing role of artificial intelligence in accelerating therapeutic innovation and addressing complex biological targets associated with cortisol dysregulation and cancer progression.
AI-Driven Drug Discovery Targets NR3C1 Pathway
The NR3C1 gene encodes the glucocorticoid receptor (GR), a critical regulator of metabolism, immune response, inflammation, and stress signaling, making it a highly promising therapeutic target across multiple disease areas. ISM6200 has been specifically engineered to selectively inhibit NR3C1, overcoming limitations of earlier-generation inhibitors such as off-target toxicity and high drug–drug interaction risks.
Using generative AI technologies, Insilico rapidly identified and optimized this small molecule candidate, achieving high selectivity, improved safety profile, and enhanced developability. The molecule’s design supports broad therapeutic applications, including oncology and cardiometabolic diseases, reflecting the power of AI-enabled precision drug discovery platforms.
Preclinical Data Demonstrate Multi-Indication Efficacy
Advertisement
In preclinical studies, ISM6200 demonstrated robust and dose-dependent anti-tumor activity, particularly when used in combination with chemotherapy agents such as paclitaxel in cell line-derived xenograft (CDX) models. The candidate also showed superior efficacy in treating Cushing’s syndrome, significantly reducing insulin resistance by 68% and normalizing blood pressure levels in animal models. Additionally, in obesity models, ISM6200 achieved notable weight loss effects, including an 8.8% reduction as monotherapy and up to 23.8% when combined with semaglutide, while preserving muscle mass. In glaucoma models, the therapy demonstrated significant reduction in intraocular pressure (IOP), further expanding its therapeutic potential. These findings underscore ISM6200’s capability as a multi-indication therapeutic candidate addressing diverse disease pathways linked to cortisol imbalance.
Pipeline Expansion and Clinical Development Outlook
The nomination of ISM6200 marks the 29th preclinical candidate (PCC) in Insilico’s growing pipeline, reflecting the company’s ability to consistently deliver high-quality AI-designed drug candidates. Since 2021, 12 candidates have achieved IND clearance, with several advancing into Phase II clinical trials, demonstrating the translational success of AI-driven discovery approaches. ISM6200’s favorable ADME/PK profile, stability, and low predicted human dose position it strongly for future clinical development.
Furthermore, the program supports Insilico’s expanding cardiometabolic and oncology portfolio, with potential applications in combination therapies and precision medicine strategies. This advancement highlights how biopharmaceutical innovation and AI integration are reshaping the drug development landscape, enabling faster, more efficient progression from discovery to clinical stages.
The nomination of ISM6200 represents a major step forward in AI-powered biopharmaceutical innovation, combining advanced computational platforms, strong preclinical validation, and multi-indication therapeutic potential. By targeting the NR3C1 pathway, Insilico Medicine is addressing critical unmet needs in oncology, metabolic disorders, and rare diseases, paving the way for more effective and personalized treatment approaches. As the candidate progresses toward clinical development, it reinforces the importance of integrating artificial intelligence with pharmaceutical research to accelerate the discovery of safer, more effective therapies.
Source: Insilico Medicine press release
